MedTrace Logo

Feasibility of Neostigmine for Intraoperative Neuromonitoring in Thyroid Surgery

NCT04873531 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-03-04

No results posted yet for this study

Summary

For successful intraoperative neuromonitoring (IONM), adequate reversal of neuromuscular blocking agent is a prerequisite in thyroid surgery with .

The aim of this study is to investigate the feasibility of neostigmine just after tracheal intubation on the IONM in thyroid surgery.

Conditions

  • Thyroid Diseases
  • Surgical Injury
  • Nerve Monitoring

Interventions

DRUG

Neostigmine

For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation. Investigators evaluate the quality of signal of IONM during the surgery.

DRUG

Normal saline

For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation. Investigators evaluate the quality of signal of IONM during the surgery.

Sponsors & Collaborators

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jung-Man Lee, MD.PhD · SMG-SNU Boramae Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2021-08-23
Completion
2021-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04873531 on ClinicalTrials.gov